What Is a Schedule 4 Medicine in Australia?

Introduction

Medicines in Australia are classified into schedules according to the level of regulatory control considered necessary for their safe use (Therapeutic Goods Administration, 2026a).

Schedule 4 medicines are prescription-only medicines under the Poisons Standard, meaning their supply is subject to prescription requirements under applicable Australian state and territory legislation (Therapeutic Goods Administration, 2026a).

The classification of a medicine as Schedule 4 does not mean that every Schedule 4 medicine has the same indication, formulation, risk profile or evidence base (Therapeutic Goods Administration, 2026a).

What does Schedule 4 mean?

Schedule 4 is the category for substances and preparations that require professional medical or dental management because of their potential risks or because their safe use requires professional knowledge, diagnosis or monitoring (Therapeutic Goods Administration, 2026a).

The Poisons Standard establishes national scheduling classifications, while states and territories administer legislation governing prescribing, possession and supply of medicines (Therapeutic Goods Administration, 2026a).

A Schedule 4 classification therefore forms part of Australia’s medicines-control framework rather than representing a statement that a particular medicine is universally suitable or effective (Therapeutic Goods Administration, 2026a).

Does Schedule 4 mean a medicine is approved?

No.

Scheduling and registration are separate regulatory concepts (Therapeutic Goods Administration, 2026a).

The Australian Register of Therapeutic Goods (ARTG) contains therapeutic goods that are included in the Australian regulatory system, subject to the applicable regulatory framework (Therapeutic Goods Administration, 2026a).

A medicine’s scheduling status therefore should not be confused with ARTG inclusion or with approval for a particular indication (Therapeutic Goods Administration, 2026a).

Why is a prescription required?

Prescription requirements provide a mechanism for medicines requiring professional assessment to be supplied within the relevant prescribing framework (Therapeutic Goods Administration, 2026a).

The need for a prescription does not mean that a medicine is appropriate for every person who requests it (Therapeutic Goods Administration, 2026a).

Clinical decisions about whether a prescription is appropriate are made by the relevant authorised health practitioner within the applicable legal and professional framework.

Why does advertising matter?

Australian law places significant restrictions on advertising prescription medicines to the general public (Therapeutic Goods Administration, 2026b).

The TGA states that the Therapeutic Goods Act 1989 generally prohibits advertising prescription medicines to the public except in limited circumstances (Therapeutic Goods Administration, 2026b).

The TGA also states that advertising a health service involving prescription medicines must not directly or indirectly refer to those prescription medicines, subject to limited exceptions (Therapeutic Goods Administration, 2026c).

These requirements are separate from the professional advertising obligations that can apply to regulated health services under the National Law (Ahpra and National Boards, 2020).

What does this mean for consumers?

Consumers should distinguish between information about a medicine and advertising intended to promote its use or supply (Therapeutic Goods Administration, 2026b).

Scientific information should also be assessed according to the quality and type of evidence supporting the claims being made (Page et al., 2021).

A medicine being prescription-only does not mean that every claim made about it online is medically established or that every person discussing it online is authorised to prescribe it.

Key takeaway

Schedule 4 identifies medicines requiring prescription-level control under Australia’s poisons-scheduling framework (Therapeutic Goods Administration, 2026a).

It does not by itself establish that a medicine is approved for every proposed use, nor does it establish that a particular treatment is appropriate for an individual.

References

• Ahpra and National Boards (2020) Guidelines for advertising a regulated health service. Australian Health Practitioner Regulation Agency.
• Page, M.J. et al. (2021) ‘The PRISMA 2020 statement: an updated guideline for reporting systematic reviews’, BMJ, 372, n71. Read at bmj.com
• Therapeutic Goods Administration (2026a) Poisons Standard. Australian Government Department of Health, Disability and Ageing.
• Therapeutic Goods Administration (2026b) Complying with the restrictions on advertising prescription medicines to the public. Australian Government Department of Health, Disability and Ageing.
• Therapeutic Goods Administration (2026c) Advertising health services that involve therapeutic goods. Australian Government Department of Health, Disability and Ageing.

Related reading

• Peptides in Australia: Understanding Schedule 4 Prescription-Only Medicines
• What Is the ARTG? Understanding Australia's Register of Therapeutic Goods
• Approved vs Unapproved Therapeutic Goods: What Is the Difference?